Identification of protein biomarkers for prediction of response to platinum-based treatment regimens in non-small cell lung cancer

ABSTRACT: The majority of stage IIA-IIIA non-small cell lung cancer (NSCLC) patients eligible for surgery are treated with platinum-based adjuvant chemotherapy (ACT) in a one-size-fits-all approach. However, a significant number of patients do not benefit due to acquired or intrinsic drug resistance. No predictive patient selection biomarker is currently available for platinum treatment. Therefore, the aim of this study was to identify protein markers that can aid in pinpointing NSCLC patients likely to derive clinical benefit from adjuvant therapy with platinum. Using global, label-free mass spectrometry-based proteomics, we have profiled archived primary tumor resection material (FFPE) of 2 independent, multi-center cohorts of in total 77 NSCLC patients, and then correlated protein expression profiles to clinical outcome in order to develop a predictor of recurrence-free survival (RFS).

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Lung

SUBMITTER: Thang Pham  

LAB HEAD: Connie Jimenez

PROVIDER: PXD043078 | Pride | 2026-10-26

REPOSITORIES: Pride